Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000

Pathologie-biologie
F Cervantes

Abstract

Median survival of patients with myelofibrosis with myeloid metaplasia (MMM) ranges from 3.5 to 5 years, but there is a wide variability. The degree of anemia (Hb < 10 g/dL) is the most important prognostic factor, followed by constitutional symptoms and abnormal karyotype. In recent years, different prognostic scoring systems for MMM have been proposed. In some of them three prognostic groups (low, intermediate, and high risk) are recognized, while others recognize a high and a low-risk group only. Median survival of the low-risk group ranges from seven to nine years, while the minority of high-risk patients survive for a median of less than two years. Younger patients with MMM survive longer (median survival above ten years). Among the latter patients, based on Hb value, constitutional symptoms, and blood blast-cell percentage, two prognostic groups can also be identified, with median survival of less than three years and almost 15 years, respectively. Conventional treatment of MMM is mostly palliative and based on cytolytic treatment (usually hydroxyurea), androgen therapy and splenectomy in selected patients. Allogeneic hemopoietic transplant is a therapeutic possibility with the potential for cure in younger patients with ...Continue Reading

References

Dec 1, 1988·British Journal of Haematology·G BarosiE Ascari
May 1, 1983·British Journal of Haematology·O S NjokuE C Gordon-Smith
Sep 15, 1993·Journal of the National Cancer Institute·A TefferiM M Ames
Mar 1, 1993·British Journal of Haematology·G BarosiR Guarnone
Jun 1, 1997·British Journal of Haematology·F CervantesE Montserrat

❮ Previous
Next ❯

Citations

Nov 15, 2002·International Journal of Hematology·Ruben A Mesa
Nov 19, 2014·Evidence-based Child Health : a Cochrane Review Journal·Surendra K SharmaPrathap Tharyan
Jun 11, 2004·Seminars in Hematology·John M McCarty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.